

Supplementary Table 4. Demographic and Clinical Characteristics before Matching

Characteristics		Unmatched	
		Non-D2T UC (n = 1,996)	D2T UC (n = 401)
Age (yr)	Median (IQR)	47 (33–60)	44 (28–57)
	≥ 65 yr	401 (20.1)	65 (16.2)
Sex	Male	1,118 (56.0)	244 (60.8)
	Female	878 (44.0)	157 (39.2)
Age at diagnosis of UC (yr)	Median (IQR)	44 (30–57)	41 (26–55)
	≥ 65 yr	314 (15.7)	47 (11.7)
Duration of disease (day)	Median (IQR)	772.5 (360–1,557)	626 (253–1,385)
	≥ 2 yr	1,041 (52.2)	182 (45.4)
Extent of disease	Extensive	653 (32.7)	164 (40.9)
	Left-sided	210 (10.5)	47 (11.7)
	Proctosigmoiditis	43 (2.2)	7 (1.7)
	Proctitis	68 (3.4)	16 (4.0)
	Unknown	1,022 (51.2)	167 (41.6)
Extraintestinal manifestation	Yes	358 ^a (17.9)	60 ^a (15.0)
Treatment for 6 mo prior to the index date			
5-ASA	Yes	1,654 (82.9)	340 (84.8)
Duration of 5-ASA (day)	Median (IQR)	151 (32.8–176)	140 (24–174)
	< 1 mo	491 (24.6)	107 (26.7)
	≥ 1 mo	1,505 (75.4)	294 (73.3)
Corticosteroids	Yes	1,225 (61.4)	293 (73.1)
Duration of corticosteroids (day)	Median (IQR)	16 (0–78)	28 (0–91)
	< 1 mo	1,174 (58.8)	205 (51.1)
	1 to < 3 mo	373 (18.7)	91 (22.7)
	≥ 3 mo	449 (22.5)	105 (26.2)
Cumulative dose of corticosteroids (mg)	Median (IQR)	420 (0–1,205)	770 (0–1,550)
	< 1,800	1,744 (87.4)	323 (80.5)
	≥ 1,800	252 (12.6)	78 (19.5)
Maximum daily dose of corticosteroids (mg/day)	Median (IQR)	15 (0–40)	30 (0–55)
	0	771 (38.6)	108 (26.9)
	> 0 to < 10	119 (6.0)	22 (5.5)
	10 to < 20	128 (6.4)	11 (2.7)
	20 to < 30	146 (7.3)	23 (5.7)
	≥ 30	832 (41.7)	237 (59.1)
Thiopurines	Yes	786 (39.4)	195 (48.6)
Duration of thiopurines (day)	Median (IQR)	0 (0–113)	0 (0–133)
	0	1,210 (60.6)	206 (51.4)
	1 to < 3 mo	228 (11.4)	59 (14.7)
	≥ 3 mo	558 (28.0)	136 (33.9)
PPIs	Yes	960 (48.1)	203 (50.6)
Duration of PPIs (day)	Median (IQR)	0 (0–106)	3 (0–85)
	0	1,036 (51.9)	198 (49.4)
	1 to < 3 mo	407 (20.4)	106 (26.4)
	≥ 3 mo	553 (27.7)	97 (24.2)

(Continued to the next page)

Supplementary Table 4. Continued

Characteristics		Unmatched	
		Non-D2T UC (n = 1,996)	D2T UC (n = 401)
Treatment on the index date			
5-ASA	Yes	1,081 (54.2)	217 (54.1)
Corticosteroids	Yes	798 (40.0)	194 (48.4)
Thiopurines	Yes	429 (21.5)	94 (23.4)
PPIs	Yes	594 (29.8)	123 (30.7)
Medical institution (beds)			
	< 200	99 (5.0)	20 (5.0)
	200 to < 500	909 (45.5)	138 (34.4)
	≥ 500	988 (49.5)	243 (60.6)
Index year			
	2018	486 (24.3)	53 (13.2)
	2019	687 (34.4)	99 (24.7)
	2020	667 (33.4)	115 (28.7)
	2021	156 (7.8)	88 (21.9)
	2022	0	44 (11.0)
	2023	0	2 (0.5)

Values are presented as number (%) unless otherwise indicated.

^aNumber of patients with D2T UC and non-D2T UC by extraintestinal manifestations (including patients with 2 or more extraintestinal complications): scleritis in 0 and 3, iridocyclitis in 0 and 1, deep venous thrombosis in 22 and 113, primary sclerosing cholangitis in 2 and 11, autoimmune pancreatitis in 6 and 28, linear IgA dermatosis in 0 and 0, psoriatic arthritis in 0 and 8, erythema nodosum in 2 and 11, pyoderma gangrenosum in 1 and 10, rheumatoid arthritis in 26 and 198, ankylosing spondylitis in 1 and 11, and sacroiliitis in 0 and 0.

D2T, difficult-to-treat; UC, ulcerative colitis; IQR, interquartile range; 5-ASA, 5-aminosalicylates; PPI, proton pump inhibitor.